Company intelligence / Profile preview

Shanghai Jiangxia Blood Products

Shanghai, Shanghai, China

Ownership: Private
Employees: ~3350
Development stage: Other

Overview

Shanghai RAAS is a leading Chinese blood products manufacturer with extensive commercialized biologics including human albumin, immunoglobulins, coagulation factors, and a monoclonal antibody (SR604) for hemophilia and rare bleeding disorders approaching Phase 1 clinical testing as of June 2025[7][8].

Therapeutic areas: HematologyImmunologyGastroenterology
Modalities: BiologicProteinMonoclonal antibodyPlasma-derived therapyRecombinant protein
Industry: Biotech

Partnerships

Boehringer Ingelheim

Beyond the preview

Go deeper on Shanghai Jiangxia Blood Products.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Jiangxia Blood Products.

Explore the full profile